PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 31370878-2 2019 Nevertheless, it is difficult to achieve stable pharmacokinetics with the current DNA-demethylating agents, azacitidine (AZA) and decitabine (DAC), because of their rapid deamination by cytidine deaminase in vivo and spontaneous hydrolytic cleavage. Azacitidine 108-119 cytidine deaminase Homo sapiens 186-204 20227960-1 1980 Cytidine deaminase, an enzyme found in the supernatant fluid of hepatocytes, granulocytes and tumor cells, and in plasma, degrades the antitumor agents cytosine arabinoside and 5-azacytidine. Azacitidine 177-190 cytidine deaminase Homo sapiens 0-18 4128550-0 1973 Deamination of 5-azacytidine by a human leukemia cell cytidine deaminase. Azacitidine 15-28 cytidine deaminase Homo sapiens 54-72 33509443-17 2021 Relatively low response rates and association of clinical benefit with low plasma levels of the aza inactivating enzyme CDA suggest the aza regimen will need to be optimized further and pt selection may be required to maximize benefit. Azacitidine 96-99 cytidine deaminase Homo sapiens 120-123 33509443-17 2021 Relatively low response rates and association of clinical benefit with low plasma levels of the aza inactivating enzyme CDA suggest the aza regimen will need to be optimized further and pt selection may be required to maximize benefit. Azacitidine 136-139 cytidine deaminase Homo sapiens 120-123 21598398-1 2011 Cytidine deaminase (EC 3.5.4.5, CDA), an enzyme of the pyrimidine salvage pathways, is responsible for the degradation and inactivation of several cytidine-based antitumor drugs such as cytarabine, gemcitabine, decitabine, and azacytidine. Azacitidine 227-238 cytidine deaminase Homo sapiens 0-18 51655-4 1975 Purification by calcium phosphate gel elution and DEAE chromatography effectively separated this enzyme from cytidine deaminase, which deaminates both CdR and ara-C, and from uridine-cytidine kinase, the enzyme which phosphorylates 5-azacytidine. Azacitidine 232-245 cytidine deaminase Homo sapiens 109-127 4521417-1 1974 Cytidine deaminase, an enzyme that catalyses the deamination of both cytidine and its nucleoside analogues including the antineoplastic agents cytosine arabinoside (ara-C) and 5-azacytidine (5-azaC), has been partially purified from normal and leukemic human granulocytes. Azacitidine 176-189 cytidine deaminase Homo sapiens 0-18 4521417-1 1974 Cytidine deaminase, an enzyme that catalyses the deamination of both cytidine and its nucleoside analogues including the antineoplastic agents cytosine arabinoside (ara-C) and 5-azacytidine (5-azaC), has been partially purified from normal and leukemic human granulocytes. Azacitidine 191-197 cytidine deaminase Homo sapiens 0-18 4521417-5 1974 Cytidine deaminase from normal human granulocytes has a greater affinity for its physiologic substrate cytidine (K(m) = 1.1 x 10(-5) M) than for ara-C (8.8 x 10(-5) M) or 5-azaC (4.3 x 10(-4) M). Azacitidine 171-177 cytidine deaminase Homo sapiens 0-18 33509443-11 2021 Achieving at least minor response and reaching TTP > 6 months was associated with approximately 35% lower median plasma levels of the enzyme that inactivates aza, plasma cytidine deaminase (CDA, P< .0001). Azacitidine 158-161 cytidine deaminase Homo sapiens 170-188 33509443-11 2021 Achieving at least minor response and reaching TTP > 6 months was associated with approximately 35% lower median plasma levels of the enzyme that inactivates aza, plasma cytidine deaminase (CDA, P< .0001). Azacitidine 158-161 cytidine deaminase Homo sapiens 190-193 31370878-2 2019 Nevertheless, it is difficult to achieve stable pharmacokinetics with the current DNA-demethylating agents, azacitidine (AZA) and decitabine (DAC), because of their rapid deamination by cytidine deaminase in vivo and spontaneous hydrolytic cleavage. Azacitidine 121-124 cytidine deaminase Homo sapiens 186-204 25850965-2 2015 Azacytidine is a pyrimidine derivative that undergoes metabolic detoxification driven by cytidine deaminase (CDA), a liver enzyme whose gene is prone to genetic polymorphism, leading to erratic activity among patients. Azacitidine 0-11 cytidine deaminase Homo sapiens 89-107 26556583-0 2015 Yin and yang of cytidine deaminase roles in clinical response to azacitidine in the elderly: a pharmacogenetics tale. Azacitidine 65-76 cytidine deaminase Homo sapiens 16-34 26556583-2 2015 Azacitidine is metabolized by cytidine deaminase, coded by a highly polymorphic gene. Azacitidine 0-11 cytidine deaminase Homo sapiens 30-48 26556583-8 2015 These polymorphisms lead to opposite clinical outcomes in patients with myelodysplastic syndromes treated with azacitidine, thus suggesting that determining cytidine deaminase status could help to forecast clinical outcome. Azacitidine 111-122 cytidine deaminase Homo sapiens 157-175 31040918-0 2019 The augmented expression of the cytidine deaminase gene by 5-azacytidine predicts therapeutic efficacy in myelodysplastic syndromes. Azacitidine 59-72 cytidine deaminase Homo sapiens 32-50 31040918-2 2019 Cytidine deaminase (CDA) is a key enzyme in the detoxification of 5AC. Azacitidine 66-69 cytidine deaminase Homo sapiens 0-18 31040918-2 2019 Cytidine deaminase (CDA) is a key enzyme in the detoxification of 5AC. Azacitidine 66-69 cytidine deaminase Homo sapiens 20-23 31040918-3 2019 We investigated whether the CDA expression could predict response to 5AC in MDS. Azacitidine 69-72 cytidine deaminase Homo sapiens 28-31 31040918-4 2019 Among leukemia-derived cell lines, MDS-L, an MDS-derived cell line with a relatively low CDA expression level, was found to be the most sensitive to 5AC. Azacitidine 149-152 cytidine deaminase Homo sapiens 89-92 31040918-5 2019 Combination with tetrahydrouridine, an inhibitor of CDA, synergistically potentiated the cytotoxic effect of 5AC. Azacitidine 109-112 cytidine deaminase Homo sapiens 52-55 31040918-7 2019 We further compared the protein expression levels of CDA in matched clinical samples before and after treatment with 5AC in bone marrow cells from 8 MDS patients by an immunohistochemical analysis. Azacitidine 117-120 cytidine deaminase Homo sapiens 53-56 31040918-8 2019 The CDA expression level showed an approximately 2- to 3-fold increase after 5AC treatment in 3 of these cases, and these three patients with relatively higher CDA expression levels after 5AC treatment all showed better clinical responses to 5AC. Azacitidine 77-80 cytidine deaminase Homo sapiens 4-7 31040918-8 2019 The CDA expression level showed an approximately 2- to 3-fold increase after 5AC treatment in 3 of these cases, and these three patients with relatively higher CDA expression levels after 5AC treatment all showed better clinical responses to 5AC. Azacitidine 77-80 cytidine deaminase Homo sapiens 160-163 31040918-8 2019 The CDA expression level showed an approximately 2- to 3-fold increase after 5AC treatment in 3 of these cases, and these three patients with relatively higher CDA expression levels after 5AC treatment all showed better clinical responses to 5AC. Azacitidine 188-191 cytidine deaminase Homo sapiens 4-7 31040918-8 2019 The CDA expression level showed an approximately 2- to 3-fold increase after 5AC treatment in 3 of these cases, and these three patients with relatively higher CDA expression levels after 5AC treatment all showed better clinical responses to 5AC. Azacitidine 188-191 cytidine deaminase Homo sapiens 160-163 31040918-8 2019 The CDA expression level showed an approximately 2- to 3-fold increase after 5AC treatment in 3 of these cases, and these three patients with relatively higher CDA expression levels after 5AC treatment all showed better clinical responses to 5AC. Azacitidine 188-191 cytidine deaminase Homo sapiens 4-7 31040918-8 2019 The CDA expression level showed an approximately 2- to 3-fold increase after 5AC treatment in 3 of these cases, and these three patients with relatively higher CDA expression levels after 5AC treatment all showed better clinical responses to 5AC. Azacitidine 188-191 cytidine deaminase Homo sapiens 160-163 30535046-8 2019 Azacytidine with ssRNA induced tumor necrosis factor-alpha expression in U937 and PBLs in a manner dependent on CDA and TLR8. Azacitidine 0-11 cytidine deaminase Homo sapiens 112-115 25850965-2 2015 Azacytidine is a pyrimidine derivative that undergoes metabolic detoxification driven by cytidine deaminase (CDA), a liver enzyme whose gene is prone to genetic polymorphism, leading to erratic activity among patients. Azacitidine 0-11 cytidine deaminase Homo sapiens 109-112 25850965-4 2015 No clinical data have been available thus far on the relationships between CDA PM status and toxicities in azacytidine-treated patients. Azacitidine 107-118 cytidine deaminase Homo sapiens 75-78 25850965-5 2015 Here, we measured CDA activity in a case of severe toxicities with fatal outcome in a patient undergoing standard azacytidine treatment. Azacitidine 114-125 cytidine deaminase Homo sapiens 18-21 25850965-7 2015 This case report calls for further prospective studies investigating the exact role that CDA status plays in the clinical outcome of patients treated with azacytidine. Azacitidine 155-166 cytidine deaminase Homo sapiens 89-92 25495470-4 2015 AREAS COVERED: Among the antimetabolites, a small but widely prescribed number of drugs (i.e., gemcitabine, capecitabine, cytarabine, azacytidine) share a same metabolic pattern driven by a liver enzyme, cytidine deaminase (CDA), coded by a gene displaying several genetic and epigenetic polymorphisms. Azacitidine 134-145 cytidine deaminase Homo sapiens 204-222 25495470-4 2015 AREAS COVERED: Among the antimetabolites, a small but widely prescribed number of drugs (i.e., gemcitabine, capecitabine, cytarabine, azacytidine) share a same metabolic pattern driven by a liver enzyme, cytidine deaminase (CDA), coded by a gene displaying several genetic and epigenetic polymorphisms. Azacitidine 134-145 cytidine deaminase Homo sapiens 224-227 23287564-0 2013 Increased CDA expression/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine therapy. Azacitidine 140-153 cytidine deaminase Homo sapiens 10-13 24045660-3 2013 The subcutaneous dosing route for consecutive days and reduced bioavailability of 5-azacytidine because of inactivation by cytidine deaminase may limit the expansion of epigenetic therapy into Phase III trials. Azacitidine 82-95 cytidine deaminase Homo sapiens 123-141 23479503-3 2013 Clinically, CDD overexpression appears particularly suited to optimize treatment strategies for acute leukemias and myelodysplasias given the efficacy of ara-C (and to a lesser degree decitabine and azacytidine) in these disease entities. Azacitidine 199-210 cytidine deaminase Homo sapiens 12-15 23287564-5 2013 EXPERIMENTAL DESIGN: Cytidine deaminase (CDA) rapidly inactivates 5-azacytidine/decitabine. Azacitidine 66-79 cytidine deaminase Homo sapiens 21-39 23287564-5 2013 EXPERIMENTAL DESIGN: Cytidine deaminase (CDA) rapidly inactivates 5-azacytidine/decitabine. Azacitidine 66-79 cytidine deaminase Homo sapiens 41-44 23287564-13 2013 CONCLUSIONS: Increased CDA expression/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine therapy. Azacitidine 153-166 cytidine deaminase Homo sapiens 23-26